UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

British journal of haematology, 2021-03, Vol.192 (6), p.1049-1053

2021

Volltextzugriff (PDF)

A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)

Blood, 2015-07, Vol.126 (4), p.500-503

2015

Volltextzugriff (PDF)

Crystalglobulinemia in Multiple Myeloma: A Rare Case Report of Survival and Renal Recovery

Canadian journal of kidney health and disease, 2020-01, Vol.7, p.2054358120922629

2020

Volltextzugriff (PDF)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

Journal of clinical oncology, 2021-11, Vol.39 (32), p.3602-3612

2021

Volltextzugriff (PDF)

Assessment of immunological anti‐platelet factor 4 antibodies for vaccine‐induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients

Journal of thrombosis and haemostasis, 2022-12, Vol.20 (12), p.2896-2908

2022

Volltextzugriff (PDF)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma

Blood advances, 2023-07, Vol.7 (14), p.3531-3539

2023

Volltextzugriff (PDF)

Ximelagatran: direct thrombin inhibitor

Vascular health and risk management, 2006, Vol.2 (1), p.49-58

2006

Volltextzugriff (PDF)

Platelet function testing in uraemic patients

Hematology (Luxembourg), 2008-02, Vol.13 (1), p.49-58

2008

Volltextzugriff (PDF)

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)

Leukemia & lymphoma, 2017-02, Vol.58 (2), p.298-307

2017

Volltextzugriff (PDF)

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

The lancet oncology, 2016-01, Vol.17 (1), p.27-38

2016

Volltextzugriff (PDF)

Ximelagatran, direct thrombin inhibitor, oral anticoagulants, thromboprophylaxis

Vascular health and risk management, 2006-01, Vol.2 (1), p.49-58

2006

Volltextzugriff (PDF)

A retrospective validation of ROTEM algorithms for detecting hyperfibrinolysis demonstrates poor agreement for prediction of in-hospital mortality and transfusion requirement in a general, non-cardiac, surgical population

Thrombosis research, 2023-09, Vol.229, p.170-177

2023

Volltextzugriff (PDF)

Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.338-338

2023

Volltextzugriff (PDF)

A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies

European journal of haematology, 2024-07, Vol.113 (4), p.521-529

2024

Volltextzugriff (PDF)

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7261-7263

2022

Volltextzugriff (PDF)

Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

Blood, 2021-11, Vol.138 (Supplement 1), p.1633-1633

2021

Volltextzugriff (PDF)

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.817-817

2021

Volltextzugriff (PDF)

Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis

Blood, 2019-11, Vol.134 (Supplement_1), p.1620-1620

2019

Volltextzugriff (PDF)

P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S188-S189

2023

Volltextzugriff (PDF)

Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma

European journal of clinical pharmacology, 2022-12, Vol.78 (12), p.1911-1921

2022

Volltextzugriff (PDF)

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.925-925

2019

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)
Berichte
(1)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

Crystalglobulinemia in Multiple Myeloma: A Rare Case Report of Survival and Renal Recovery

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Assessment of immunological anti‐platelet factor 4 antibodies for vaccine‐induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma

Ximelagatran: direct thrombin inhibitor

Platelet function testing in uraemic patients

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Ximelagatran, direct thrombin inhibitor, oral anticoagulants, thromboprophylaxis

A retrospective validation of ROTEM algorithms for detecting hyperfibrinolysis demonstrates poor agreement for prediction of in-hospital mortality and transfusion requirement in a general, non-cardiac, surgical population

Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study

A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis

P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma

Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Suchergebnisse filtern